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Abstract
The electrochemical characterization of sertraline at gold electrode was examined by cyclic voltammetry measurements (CV) 
in pH 8.4 bicarbonate buffer. Then Au electrode was evaluated for the quantitative determination of sertraline using square 
wave voltammetry (SWV). To enhance the sensitivity during the drug determination, (2-hydroxypropyl)-β-cyclodextrin 
(HPβCD) and β-cyclodextrin (βCD) inclusion complexes were employed. Using the proposed SWV technique, the anodic 
current peak was linear within a concentration range of 0.1–0.5 µM with a limit of detection (LOD) of 2.0 × 10–8 M and 
a limit of quantification (LOQ) of 6.7 × 10–8 M. In the case of inclusion complex of the sertraline with HPβCD, a good 
linearity range of 0.1–0.9 µM was obtained with a LOD of 2.6 × 10–8 M and a LOQ of 8.8 × 10–8 M. The gold electrode 
revealed the same linearity range for inclusion complex of the sertraline with βCD with a LOD and a LOQ being 2.6 × 10–8 
and 8.6 × 10–8 M, respectively. Comparing the regression equations, it can be concluded that the sensitivity in the presence 
of inclusion complex can be up to 5 times higher. The applicability of the developed method was confirmed by the analysis 
of this drug in pharmaceutical formulation and in human serum spiked with sertraline standard. The comparison to HPLC 
method was successfully performed.
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Introduction
Sertraline hydrochloride in pharmaceutical formulation, 
sold under the brand name (Sidata, Zoloft, Lustral), is an 
antidepressant in the class of selective serotonin-reuptake 
inhibitors (Fig. 1) [1–3]. Serotonin is a neurotransmitter and 
is considered a happiness hormone. Numerous serotonin-
reuptake inhibitors are effective and used in the treatment 
of depression, including sertraline. Sertraline is primarily 
used to treat clinical depression in adult patients, as well 
as obsession, panic disorder, and social phobia in adults 
and children. It is used orally and therapeutic doses of ser-
traline are 5–200 mg day−1 for four weeks, thus providing 
80–90% inhibition of the serotonin transporter in the stria-
tum [4]. Studies have shown an increase in the concentration 
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of amphetamines in the brain of rats pretreated with 
5 mg kg−1 sertraline [5]. The drug is metabolized by the liver 
(N-demethylation) with a half-life of 26 h. It is excreted by 
the kidneys.
There is an increasing demand for rapid tests for the 
determination of trace concentrations of sertraline. In this 
context, different electrochemical methods showed a particu-
lar potential for practical applications in biomedical analy-
ses. Square wave voltammetry (SWV) with electrodeposi-
tion at a hanging mercury drop electrode proved suitable 
for the determination of this drug in pharmaceutical for-
mulations [6]. Using a pH 8.2 borate buffer for the samples 
containing 12% (v/v) methanol, a linear relationship between 
2.33 × 10–7 and 3.15 × 10–6 M was obtained. A method using 
adsorptive voltammetry and a hanging mercury drop elec-
trode flow cell can also been applied for the determination of 
sertraline in the concentration interval between 0.20 × 10–6 
and 1.20 × 10–6 M [7]. Dermiş and Cay investigated the 
electrooxidation of this drug on a glassy carbon electrode 
(GCE) in pH 8 Britton-Robinson buffer-methanol support-
ing electrolyte using SWV [8]. A linear peak current–con-
centration relationship was found in the range from 0.04 
to 0.8 mM. A rutin-modified GCE demonstrated the cata-
lytic capability for the oxidation of sertraline, whereby the 
anodic current linearly related to the drug concentration in 
the range from 3.0 to 90.0 μM [9]. Shoja et al. described 
an innovative strategy for the determination of sertraline 
where nano-structured Ni(II)-levodopa film was electropo-
lymerized on a GCE which was previously modified by gold 
nanoparticle-enriched multi-walled carbon nanotubes in an 
alkaline solution [10]. Namely, this nanostructure film was 
effective for the electrocatalytic oxidation of the drug and 
differential pulse voltammetry (DPV) was used for its deter-
mination in the range from 0.05 to 5.5 mM. On the basis of 
the electrooxidation of sertraline hydrochloride at a carbon 
paste electrode in presence of micellar medium, composed 
of a pH 7 Britton-Robinson buffer and Triton X-100, an 
analytical method was developed using square wave vol-
tammetry for the determination of the drug [11]. Here, a 
linear relationship response was obtained from 1.99 × 10–7 
to 1.38 × 10–5 M. A method for multiclass drug analysis 
using a biphenyl stationary phase and pulsed amperometric 
detection at a gold electrode was described by Muratt et al. 
[12]. This method enabled the determination of fourteen 
drugs as adulterants in dietary supplement samples, among 
which sertraline in the range from 3.00 to 70.00 mg dm−3. 
Recently, Babaei et al. developed a GCE modified with a 
composition of  Fe3O4@MCM-48-SO3H and multi-wall car-
bon nanotubes for simultaneous determination of serotonin 
and sertraline in the presence of uric acid [13]. The DPV 
results showed a linear relationship between the concentra-
tion of sertraline and the anodic peak current in the range 
from 0.1 to 85 µM. A  La2O3/Co3O4 nanocomposite modi-
fied screen-printed electrode enabled the determination of 
sertraline in a pH 7 phosphate buffer also using DPV [14]. In 
this case, the anodic peak current was increased linearly with 
the drug concentration in the range from 5.0 to 400.0 µM.
The importance of pharmaceutical application of cyclo-
dextrins as drug carriers has been recognized for a long time 
[15]. Cyclodextrins, acting as hosts, are able to increase the 
solubility of the sparingly soluble compounds and thus, in 
the case of drugs, to enhance their bioavailability [16, 17]. 
Also, some other properties can be improved, such as resist-
ance to light [18], organoleptic properties [19], as well as 
enhanced drug permeation [20]. Among diverse cyclodex-
trins, βCD has shown a significant ability in drug-sensing 
applications [21–23].
The aim of this work is to develop an electrochemical 
method using a gold electrode for quantitative determina-
tion of sertraline in pharmaceutical formulations and spiked 
serum. The method is based on the electrochemical oxida-
tion of sertraline as the standard and its inclusion complexes 
(HPβCD, βCD) in a pH 8.4 bicarbonate buffer using SWV. 
The biologically relevant range of sertraline concentra-
tions was examined and detailed statistical parameters of 
the obtained results are summarized and compared to the 
HPLC method.
Results and discussion
The use of CD complexes with pharmaceutically active com-
pounds is attractive for the preparation of electrochemical 
sensors especially in pharmaceutical and biomedical analy-
sis. It has been shown that cyclodextrin represents a non-
electroactive host while pharmaceutical compounds are an 
electroactive guests [24–27].
In this work, the Au electrode was tested for the oxida-
tion and determination of sertraline in a  NaHCO3 solution. 
The sertraline:CD inclusion complexes were prepared and 
used for sertraline electrooxidation ability improvement. It 
was proven that the complexation process of sertraline:CD 
Fig. 1  The structure of sertraline hydrochloride
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system is spontaneous and exothermic [28–30]. The most 
investigated systems with sertraline are complexes formed 
with βCD [31]. The stoichiometry of βCD or HPβCD com-
plexes with sertraline is close to 1:1 with a negligible amount 
of 2:1 [28, 29] indicating that these CDs allow entrapment 
of one molecule of sertraline into the cavity. The high affin-
ity of βCD in water is confirmed by the values of binding 
constants that vary from 5300 to 5900 M−1 depending on the 
used technique while the association constant for complex 
sertralin:HPβCD is 6530 M−1 [29]. Also, characterization of 
sertraline:βCD complex in solid state indicates a formation 
of 1:1 IC. It is also shown that possible interactions of the 
sertraline molecule with CD molecules include N-methyl 
unit as well as aromatic rings, especially fused aromatic ring 
[31, 32].
Figure 2 presents CVs for the oxidation of sertraline and 
its inclusion complexes with HPβCD as well as the voltam-
mogram of the Au electrode in the blank solution for the 
sake of comparison. The electrochemical behavior of Au 
was described by taking into account adsorption processes, 
such as chemisorption of  OH−, which occurred in the poten-
tial region of -0.1 to + 0.3 V vs. SCE followed by the oxide 
formation at more positive potentials [33]. The onset poten-
tial for the oxidation of sertraline and its inclusion complex 
with HPβCD were correlated with formation of AuOH spe-
cies. Also in the region of the AuOH layer, formation higher 
reaction currents were obtained with inclusion complexes 
of sertraline indicating the improvement of sertraline elec-
trooxidation ability in the presence of HPβCD. The simi-
lar improvement of the oxidation abilities we reported for 
inclusion complexes of nifedipine and amlodipine also at 
Au electrode [34] as well as for arylazo pyridone dyes [35].
It was published that the electrochemical oxidation of 
sertraline on a rutine/glassy carbon electrode (GCE) is an 
irreversible 2e/2H+ reaction [9]. The deprotonation of the 
sertraline molecule proceeds at the cyclohexane unit at α 
carbon to methyl amino group. It seems that the formation 
of the inclusion complex of the sertraline with HPβCD leads 
to an easier deprotonation during electrochemical oxidation. 
At more positive potentials (E > 450 mV), anodic currents 
for the sertraline and its inclusion complex with HPβCD 
oxidation decrease in regard to the Au electrode in blank 
solution. It shows their inhibiting effect on the Au oxide 
formation obviously attributed to the presence of sertraline 
and diminished during complexation with HPβCD. The peak 
of oxide reduction also decreases in comparison to the oxide 
reduction of the Au electrode in a blank solution. The same 
electrochemical response was obtained when sertraline is 
complexed with βCD, while the reaction currents are some-
what lower in regard to inclusion complex with HPβCD.
For quantitative determination of sertraline, the SWV 
technique was employed. Figure 3a showed SWV curves 
of sertraline presented with one peak at ~100 mV. For ser-
traline concentrations higher than 0.5 µM, reaction currents 
decline due to the surface saturation with reaction species. 
The inclusion complex of sertraline with HPβCD depicts 
higher reaction currents in SWV measurements (Fig. 3b), 
as it was presented in the potentiodynamic measurements. 
As was observed by CV, the improvement of the oxidation 
ability regarding inclusion complexes was reported and also 
for SWV determination of amlodipine [34] and arylazo pyri-
done dyes [35]. Also, the peak potential was shifted towards 
more positive potentials for ~50 mV in the presence of the 
inclusion complex while the range of investigated concentra-
tions was wider.
Considering the inclusion complex of sertraline with 
βCD, SWV measurements showed the same response as it 
was obtained for the inclusion complex of sertraline with 
HPβCD but with lower peak reaction currents. The SWV 
response showed that the oxidation peak currents for the 
sertraline standard were linearly dependent on its concen-
tration in the range from 0.1 to 0.5 µM as it is presented 
in Fig.  4a. The obtained regression equation is jp/µA 
 cm−2 = 31.33 + 4.70 c/µM (R2 = 0.999, SD = 0.032 µA cm−2) 
and LOD and LOQ are 2.0 × 10–8, and 6.7 × 10–8 M, respec-
tively. On the other hand, the oxidation peak of the inclusion 
complex of sertraline with HPβCD was linearly related to 
the concentration in the range 0.1–0.9 µM (Fig. 4b) giv-
ing the regression equation jp/µA cm−2 = 40.60 + 25.55 c/
µM (R2 = 0.999, SD = 0.22 µA cm−2) and LOD and LOQ 
are 2.6 × 10–8 and 8.8 × 10–8 M, respectively. The regression 
equation obtained for the inclusion complex of the sertraline 
with βCD is jp/µA cm−2 = 25.925 + 22.75 c/µM (R2 = 0.999, 
SD = 0.20 µA cm−2) with a LOD and a LOQ being 2.6 × 10–8 
and 8.6 × 10–8 M, respectively. The LOD and LOQ values 
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Fig. 2  CVs of Au electrode with 0.3 µM sertraline (dash line), inclu-
sion complex of sertraline with HPβCD (full line), inclusion complex 
of sertraline with βCD (dash dot line) and in blank solution (dot line) 
in 0.05 M  NaHCO3. Scan rate 50 mV s−1
188 J. Lović et al.
1 3
were estimated from the regression lines as: LOD = 3 × SD/
slope, and LOQ = 10 × SD/slope.
Detailed statistical parameters of obtained calibration 
curves are summarized in the Table 1. Linearity of a signal/
concentration dependence was statistically confirmed using 
several approaches. The first approach was based on a visual 
inspection of residuals [36]. No presence of any trends, nei-
ther curvilinear, linear descending, linear ascending, nor the 
heteroscedasticity, i.e., increase in the variability of resid-
uals with the increase of the analyte’s concentration was 
observed which confirms the linearity of regression lines. 
The second approach was based on testing the conformity 
of the values of the slope calculated from each calibration 
point to the ±5% tolerance deviations from the average value 
of the slope [37]. For all three regression equations, the ±5% 
tolerance ranges of the slopes are: 4.47–4.94, 21.61–23.88, 
and 24.14–26.68 respectfully. In all three cases, all the points 
yield the slope values within these limits, which prove the 
linearity in the tested concentration range. The third way 
was based on comparison of adjusted R2 values obtained 
in the case of linear regression and those obtained for the 
curvilinear models, such as quadratic and cubic polynomi-
als [36]. The highest R2adj values, obtained in the case of 
simple linear models, prove that the linear models are the 
best fit option (Table 1). The last approach was based on 
a comparison of the variances of residuals of the linear fit 
versus the fit of higher orders, such as quadratic or cubic 
ones, by the means of the F-test (denoted as Flin/quad, and 
Flin/cub, respectively). In the case that the quadratic or cubic 
polynomials demonstrate a better fit into the calibration data, 
the F value should be statistically significant at a predefined 
significance level. Since no such statistical significance was 
observed in all three calibration models (Table 1), the linear 
fit was proven to be the best option. Comparing the regres-
sion equations, it can be noticed that the sensitivity in the 
presence of the inclusion complex was nearly 5 times higher.
Table 2 illustrates the obtained values of several impor-
tant analytical parameters, such as linear range, LOD, 
LOQ, for the determination of sertraline that can be found 
in earlier reported papers. Comparing the obtained results 
on the Au electrode to previously published results pre-
sented in Table 2, concerning the electrochemical behav-
iour of sertraline, it can be concluded that an extension of 
the linear concentration range was accomplished [6–10]. 
The inclusion complexes of sertraline with HPβCD dem-
onstrated a new electrochemical strategy for increasing 
the electrode’s sensitivity in its quantitative determination. 
In addition, the obtained values of LOD and LOQ for the 
inclusion complex of the sertraline with HPβCD are com-
parable [10, 11, 38] or more than one order of magnitude 
Fig. 3  Sertraline (a) and its inclusion complex with HPβCD (b) determined by SWV at Au (the concentrations added in electrolyte are presented 
in legend). Step size 5 mV, pulse size 25 mV and scan rate 10 mV s−1, accumulation time 30 s, at the potential (− 50 mV)
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higher than the published [6–8] as can be seen in Table 2. 
The evaluated parameters indicated a significant electro-
chemical response and possibility for analytical use. SWV 
measurements were further utilized for the quantitative 
determination of sertraline in pharmaceutical formulation 
as Sidata tablets.
Fig. 4  Dependence of jp from c (data collected from Fig. 3a) for the 
sertraline standard and its unknown concentrations in Sidata tablets 
and in human serum spiked with standard (a); and (data collected 
from Fig.  3b), for the inclusion complex of the sertraline standard 
with HPβCD and βCD
Table 1  Statistical parameters of obtained calibration models
Calibration model for SWV method A B (βCD) B (HPβCD)
Intercept, a/µA cm−2 31.33 25.92 40.62
Slope, b/µA cm−2 µM 4.70 22.75 25.55
Standard error of the intercept, sa 0.033 0.18 0.20
Standard error of the slope, sb 0.10 0.31 0.35
SD 0.032 0.20 0.22
R2 0.9986 0.9994 0.9994
F 966.8 5400.7 5187.8
p 2.1·10–5 5.6·10–6 5.9·10–6
n 5 5 5
R2adj(lin) 0.9982 0.9993 0.9992
R2adj(q) 0.9979 0.9989 0.9980
R2adj(cub) 0.9977 0.9983 0.9980
Flin/quad 0.88 0.67 0.38
p(F) 0.572 0.645 0.782
Flin/cub 0.00 0.43 0.38
p(F) 0.9999 0.7756 0.7973
Table 2  Comparison of analytical parameters of various electrodes 
for the determination of sertraline
Electrode Linear range/M LOD/M LOQ/M Reference
HMDE 2.33 × 10–7–
3.15 × 10–6
1.98 × 10–7 – [6]
HMDE 0.20 × 10–6–
1.20 × 10–6
1.5 × 10–7 5.0 × 10–7 [7]
GC 4 × 10–5–10–4 1.04 × 10–5 3.72 × 10–5 [8]
R/GC 3 × 10–6–9 × 10–5 1 × 10–6 – [9]
Ni(II)-LD/Au 5 × 10–8–
5.5 × 10–6
9.5 × 10–8 – [10]
CPE 1.99 × 10–7–
1.38 × 10–5
2.23 × 10–8 7.42 × 10–8 [11]
Pencil lead 10–7–10–6 4.5 × 10–8 – [38]
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Using the calibration curves (Fig. 4a, b), the values of 
unknown sertraline concentrations in Sidata tablets as well 
as in the human serum spiked with sertraline standard were 
determined. Prior to SWV investigations, each excipient as 
a content of pharmaceutical formulation Sidata was tested 
under the experimental conditions used in potentiodynamic 
measurements and all of them were electrochemically 
inactive.
The inclusion complexes of sertraline and Sidata with 
βCD were also investigated and the activity was compared 
to the results of sertraline and Sidata in the complex with 
HPβCD (Fig. 4b). The lower peak currents were obtained 
using βCD and the difference of the peak current of ser-
traline in the complex with HPβCD and βCD according to 
Fig. 4b was nearly 1.5 times. The observed electrochemical 
properties of sertraline in the complex with HPβCD or βCD 
were attributed to the influence of the structural parameters 
of cyclodextrins [39]. It has been shown that the presence 
of the hydroxypropyl groups additionally stabilizes the com-
plex and appropriate interactions were in greater extent than 
in the case of βCD. The stronger binding ability concerning 
the inclusion complex of the azo dye with the HPβCD in 
regard to βCD has already been reported [35].
The accuracy of the proposed method was examined by 
recovery analysis applied for the set of sertraline concentra-
tions as is presented in Table 3. The recovery, as an average 
value of 3 replicates varies from 96.74% to 102.60% and 
the relative standard deviation (R.SD) varies from 1.53% 
to 4.91%. This result indicates that the proposed electro-
chemical methods are reliable electroanalytical procedures 
for the quantification of sertraline. However, the lower rela-
tive standard deviations are obtained in the case of HPβCD 
and βCD added (1.64–2.59% and 1.53–1.68%, respectively) 
when compared to the method without the CD addition 
(4.73–4.91%).
For the quantitative detection of sertraline, the HPLC 
technique was also used. The linear response of the peak 
area to its concentration in the solution was shown in the 
range of 0.05–8 µM. The obtained regression equation is 
y = 1824.887 + 0.84398 x (R2 = 0.999, SD = 1.06) and LOD 
and LOQ are 3.0 × 10–8 and 10.0 × 10–8 M, respectively.
All SWV determined sertraline concentrations were 
confirmed by HPLC–UV and the comparison with SWV 
is presented in Table 4. The comparison of sertraline con-
centration in the Sidata tablet and its inclusion complexes 
determination by SWV to HPLC method was performed by 
the t-test for two samples assuming equal variances. The 
obtained t-values for the SWV methods A, B (HPβCD) and 
B (βCD) (1.876, 0.155, and 0.914, respectively) were lower 
than the critical t-value (2.23 for the two-tailed test at the 
predefined p = 0.05 significance level), indicating that there 
is statistically no significant difference between the electro-
chemical and the HPLC method.
Conclusion
The obtained results showed that the gold electrode dis-
played a significant electrocatalytic response to the inclusion 
complexes of cyclodextrin with sertraline as the standard 
and Sidata tablets. Using and developing the SWV method 
and comparing it to the previously published results on dif-
ferent electrode surfaces concerning electrochemical behav-
ior of sertraline, it can be concluded that the extension of 
Table 3  Recovery studies of 
sertraline
a Solution of sertraline
b Number of replicates = 3




A 0.25 (tablet powder) 0.24 96.74 4.91
0.45 (tablet powder) 0.46 102.60 4.73
0.25 (serum) 0.26 102.41 4.91
0.45 (serum) 0.44 97.87 4.73
B (HPβCD) 0.40 (tablet powder) 0.41 102.59 2.59
0.60 (tablet powder) 0.60 99.27 1.64
B (βCD) 0.40 (tablet powder) 0.41 102.29 1.68
0.60 (tablet powder) 0.61 102.14 1.53
Table 4  The determination of sertraline in Sidata tablet using the pro-
posed SWV methods
a Arithmetic mean and standard deviation of six replicates
Method Amount found 
(± SD)a/mg
SWV A 51.9 (± 2.5)
SWV B (HPβCD) 49.9 (± 1.0)
SWV B (βCD) 50.5 (± 1.1)
HPLC 50.0 (± 0.82)
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the linear concentration range was accomplished. Based on 
the constructed and statistically validated calibration curve, 
the values of unknown sertraline concentration in the Sidata 
tablet and in human serum spiked with the standard were 
determined opening perspectives for serious analytical 
applications.
Experimental
Sertraline hydrochloride, as the reference standard, and com-
mercial drug Sidata were kindly provided by Hemofarm 
Stada A.D. (Vršac, Serbia). HPβCD (97.5%) and βCD (98%) 
were purchased from Sigma-Aldrich and Merck, respec-
tively. All chemicals used were of p.a. grade. The deionized 
water is obtained by a Millipore Waters Milli-Q purification 
unit and used in all experiments.
Stock solution of the sertraline standard was prepared by 
dissolving the compound (2.918 μmol dm−3) in deionized 
water. The stock solution of Sidata was prepared by pow-
dering 10 tablets (50 mg of active compound) in a mortar. 
The adequate weight was measured and dissolved in deion-
ized water under ultrasonic. After filtration through a filter 
paper, the solution was diluted with the deionized water to 
100  cm3. Both stock solutions were stored in a refrigerator 
at 4 °C. The inclusion complexes of sertraline and Sidata 
were prepared with HPβCD and βCD in molar ratio of 1:1. 
First, cyclodextrin solutions equimolar to drug stock solu-
tions were prepared. Aliquots of equimolar solutions of the 
host and guest molecules were mixed in  NaHCO3 solutions 
to obtain a specified concentration of inclusion complexes. 
The obtained solutions were mixed for 24 h and allowed to 
equilibrate at room temperature over night before their addi-
tion to the electrochemical cell.
Human blood was collected from ten healthy volunteers 
and the serum was clinically prepared and spiked with ser-
traline standard in laboratories of Faculty of Medicine, Uni-
versity of Belgrade.
Electrochemical measurements were performed using 
PGZ 402 Volta Lab (Radiometer Analytical, Lyon, France) 
in a three-electrode cell with Au as the working electrode 
(surface area 0.5 cm2), Au wire auxiliary electrode, and a 
calomel reference electrode (SCE). The Au working elec-
trode was polished with diamond paste, cleaned with a mix-
ture of 18 MΩ water and sulfuric acid and further cleaned 
with 18 MΩ deionized water in an ultrasonic bath. The elec-
trolytes were deoxygenated by purging with nitrogen. The 
working electrode was checked prior to each experiment by 
cycling the potential scan between -400 and 1000 mV in a 
supporting solution (0.05 M  NaHCO3, pH 8.4) at the scan 
rate of 50 mV s−1 until the unchanged CV characteristics 
for the Au electrode were achieved. The accumulation of 
the samples at the Au electrode was carried out for 30 s at 
-50 mV. After that, SWV initiated in the positive potential 
direction was performed. The following parameters were 
used as the optimum to record the SWVs: step size 5 mV, 
pulse size 25 mV, frequency 2 Hz, scan rate 10 mV s−1.
The HPLC measurement was performed on Agilent 1100 
HPLC system consisting of Diode Array Detector, binary 
pump, thermostated column compartment, autosampler, and 
a micro vacuum degasser. HPLC chromatographic separa-
tion was carried out on Zorbax Eclipse XDB C-18 column 
(150 × 4.6 mm, 5 µm) using isocratic elution with the mobile 
phase consisting of a buffer solution (2.88 g of sodium dode-
cyl sulfate, 3.40 g of tetra-n-butyl ammonium hydrogen 
sulfate, and 2.76 g of sodium phosphate monobasic mono-
hydrate and transfer in 1000 cm3 water), methanol, and ace-
tonitrile in a 40:40:30 ratio. Flow rate was 2 cm3 min−1, the 
injection volume was set at 20 mm3, the column temperature 
was 40 °C and UV detection was carried out at 220 nm.
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